Carbohydrate + fat blends are estimated at 45.4% by composition in 2026, with inherited metabolic disorders at 45.6% of indication demand and powders at 51.8% of product form. Adoption depends on specialist diet design and refill continuity, while reimbursement rules and small patient pools constrain wider access.